Thiobutabarbital
From Wikipedia, the free encyclopedia
 |
|
|
Thiobutabarbital
|
|
| Systematic (IUPAC) name | |
| 5-butan-2-yl-5-ethyl-2-sulfanylidene-1,3-diazinane-4,6-dione | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C10H16N2O2S |
| Mol. mass | 228.312 g/mol |
| Synonyms | Thiobutabarbital, Inactin, Brevinarcon, 5-sec-Butyl-5-ethyl-2-thiobarbituric acid |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Thiobutabarbital (Inactin, Brevinarcon) is a short-acting barbiturate derivative invented in the 1950s. It has sedative, anticonvulsant and hypnotic effects, and is still used in veterinary medicine for induction in surgical anaesthesia [1]
[edit] References
- ^ Rieg T, Richter K, Osswald H, Vallon V. Kidney function in mice: thiobutabarbital versus alpha-chloralose anesthesia. Naunyn Schmiedebergs Archives of Pharmacology. 2004 Oct;370(4):320-3.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||
